Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
10x GenomicsTXG -0.82%58 Net-Net Working Capital is $3.06 as of Mar. 2026. GuruFocus rates TXG with a GF Score™ of 58/100 and a GF Value™ of $18.84 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 190 Healthcare Providers & Services companies, 10x Genomics ranks worse than 70.53% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
10x Genomics's Net-Net Working Capital for the quarter that ended in Mar. 2026 was $3.06.
The industry rank for 10x Genomics's Net-Net Working Capital or its related term are showing as below:
TXG's Price-to-Net-Net-Working-Capital is ranked worse than 70.53% of 190
companies
in the Healthcare Providers & Services industry
Industry Median: 7.505
vs TXG: 15.51
10x Genomics (NAS:TXG) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
10x Genomics Net-Net Working Capital Related Terms
10x Genomics Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for 10x Genomics's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TXG vs HNGE, WAY, TEM: Net-Net Working Capital Comparison
For the Health Information Services subindustry, 10x Genomics's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics Price-to-Net-Net-Working-Capital vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where 10x Genomics's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $3.06 mean?
10x Genomics (TXG) has a Net-Net Working Capital of $3.06 as of Mar. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on 10x Genomics According to the industry distribution chart, 10x Genomics ranks #134 out of 190 companies in the Healthcare Providers & Services industry, placing it in the top 70.5%.
Is 10x Genomics' Net-Net Working Capital too high?
10x Genomics' current Net-Net Working Capital is $3.06. The Healthcare Providers & Services industry median Net-Net Working Capital is 7.51. 10x Genomics' value of $3.06 is 59.2% below this industry median. Based on the distribution chart, 10x Genomics ranks #134 out of 190 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, 10x Genomics has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Net-Net Working Capital compare to HNGE and WAY?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #134 out of 190 companies for Net-Net Working Capital. This places 10x Genomics in the lower half of its industry. The industry median Net-Net Working Capital is 7.51. 10x Genomics' value of $3.06 is 59.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Healthcare Providers & Services company?
The median Net-Net Working Capital among Healthcare Providers & Services companies is 7.51, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 10x Genomics's current Net-Net Working Capital of $3.06 is 59.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on 10x Genomics For the Healthcare Providers & Services industry, the median Net-Net Working Capital is 7.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current Net-Net Working Capital is $3.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.84, compared to a current price of $47.46 — trading 151.9% above its estimated fair value. The current Net-Net Working Capital is $3.06 and 59.2% below the Healthcare Providers & Services industry median of 7.51. 10x Genomics' overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For 10x Genomics (TXG), the current Net-Net Working Capital is $3.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of $47.46 is trading 151.9% above its estimated GF Value™ of $18.84.
GuruFocus considers 10x Genomics to be Significantly Overvalued.
Key valuation signals for TXG:
Net-Net Working Capital: $3.06
GF Value™: $18.84 vs. price of $47.46 (151.9% above fair value)
Industry Position: 59.2% below the Healthcare Providers & Services median (#134 of 190)
No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
58GF Score
Get the complete analysis for TXG
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXG has been successfully added to your 
